Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23742203 | 0.85 | MEN1 (0.53) | MEN1KMT2ASIGMAR1KDM4ETDP1 | |
| SCHEMBL3866360 | 0.84 | SIGMAR1 (0.71) | KMT2ASIGMAR1KDM4ETDP1RECQL | |
| SCHEMBL21695104 | 0.83 | HRH3 (0.57) | MEN1KMT2ASIGMAR1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL3859180 | 0.83 | SIGMAR1 (0.74) | KMT2ASIGMAR1KDM4ETDP1RECQL | |
| SCHEMBL23742241 | 0.81 | MEN1 (0.49) | MEN1KMT2ASIGMAR1KDM4ETDP1 | |
| SCHEMBL21814266 | 0.77 | SIGMAR1 (0.62) | SIGMAR1KDM4ETDP1RECQLHRH3 | |
| SCHEMBL14100110 | 0.76 | ESR1 (0.49) | SIGMAR1TDP1HRH3TSHR | |
| SCHEMBL23475002 | 0.75 | HRH3 (0.47) | MEN1KMT2ASIGMAR1KDM4ETDP1 | |
| SCHEMBL23474913 | 0.75 | HRH3 (0.47) | MEN1KMT2ASIGMAR1KDM4ETDP1 | |
| SCHEMBL23474957 | 0.75 | HRH3 (0.47) | MEN1KMT2ASIGMAR1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4100400-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | Kings College London (GB) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | RIF1, NAT1, POLR1C | MEN1 342/4885KMT2A 3282/4885SIGMAR1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.